By Fineline Cube 
China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has obtained approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials for SYH2068, a Class 1 innovative small interfering RNA (siRNA) therapeutic targeting lipoprotein(a) [Lp(a)].
SYH2068 siRNA Mechanism
The GalNAc-conjugated siRNA achieves hepatic targeting via subcutaneous administration. It demonstrates enhanced gene silencing capabilities, sustained efficacy, and a favorable safety profile.
Competitive Advantages
Developed for hyperlipoproteinemia(a), SYH2068 shows competitive advantages over existing therapies. This innovative approach represents a significant advancement in treating high Lp(a) levels and related cardiovascular diseases.-Fineline Info & Tech